AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc. the privately held developer of the Lariat percutaneous left atrial appendage (LAA) closure device.
AtriCure markets surgical products including the Isolator Synergy Ablation System, the first and only device, either catheter or surgical, to receive FDA approval for the treatment of persistent atrial fibrillation,...